Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CCL5 | P13501 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14505207 | 1.00 | CCR5 (0.57) | CCR5KCNH2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL5226537 | 0.90 | CCR5 (0.55) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL5217699 | 0.88 | CCR5 (0.56) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL5224166 | 0.86 | CCR5 (0.54) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL4912503 | 0.81 | CCR5 (0.57) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL3595208 | 0.79 | CCR5 (0.61) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL4915643 | 0.77 | CCR5 (0.54) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL6012136 | 0.77 | CCR5 (0.63) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL6012135 | 0.77 | CCR5 (0.63) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL5221963 | 0.77 | CCR5 (0.57) | CCR5KCNH2CYP3A4CYP2D6CCL5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| EP-1654229-B1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1654229-B1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | CCR5, CCR2, CCR6 | CCR5 1/4885KCNH2 2301/4885CYP3A4 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.